Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
September 30, 2024
LA JOLLA, CA Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, with no clear drug-binding sites.
To design a drug that blocks a cancer-related protein, Scripps Research scientists took a hint from the protein's paralog, or twin. Using innovative chemical biology methods, the scientists pinpointed a druggable site on the paralog, and then used that knowledge to characterize drugs that bound to a similar but more difficult to detect spot on its twin. Ultimately, they found drugs that only bound to the protein of interest and not its highly similar sibling.
Their approach, described in Nature Chemical Biology on September 18, 2024, and dubbed paralog hopping, could uncover new binding sites for drugs and inform drug development more broadly, since nearly half of the proteins in human cells including many involved in cancer and autoimmune diseases have such paralogs.
This method may be generally useful in cases where you have paralogs, and you are trying to find a new drug for one of them, says senior author Benjamin Cravatt, PhD, the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research. Being able to target one paralog over another is an important goal in drug development, as two paralogs often have different functions.
Many genes have duplicated throughout evolution, resulting in multiple copies in the human genome. In some cases, copies have evolved slightly different sequences from each other, making their corresponding proteins into paralogs. These protein paralogs remain highly similar in structure and often have redundant or overlapping functions within cells.
In recent years, Cravatt's research team formulated an approach to develop drugs that bind to the amino acid cysteine a protein building block with unique, highly reactive chemical properties. The scientists' method takes advantage of cysteines as an optimal site for drugs to attach to a protein permanently, often inactivating it. However, not all proteins have accessible cysteines. In the cases of paralog pairs, one protein may have a druggable cysteine that the other does not.
We started with this idea that if you know how to drug one protein, you can figure out how to drug its paralog in a similar way, says Yuanjin Zhang, a graduate student at Scripps Research and first author of the new paper.
As a test case, the team tackled the paralog pair known as CCNE1 and CCNE2. Both proteins have been found to be overactive in breast, ovarian and lung cancer. However, scientists suspected that the two proteins play slightly different roles. The team posited that turning off just one protein could make treating some cancers more effective.
It has been difficult, however, to design drugs that target the CCNE1 and CCNE2 proteins to test this hypothesis. Cravatt, Zhang and their colleagues knew that CCNE2 had a druggable cysteine, while CCNE1 did not. If they could identify drugs that bound to the same spot on CCNE1, even in the absence of a cysteine, they suspected the protein would shut off.
The scientists first engineered a cysteine into CCNE1, mimicking the drug-binding spot they had pinpointed in CCNE2. They then leveraged this neo-cysteine to identify drugs that bind to CCNE1. Next, they screened a library of other chemical compounds for the ability to compete with that drug in binding to CCNE1. The team reasoned that some of the compounds that competed for the same spot would bind in ways that did not rely on the cysteine.
Indeed, Cravatt, Zhang and their colleagues discovered multiple compounds that could bind to the same site on CCNE1 even when the cysteine was removed again. Some compounds did not bind to CCNE2. Some also had opposite functions, stabilizing the molecule so that it might be more active than usual, rather than inactivating it. Structural studies revealed that the CCNE1 compounds bind to a cryptic pocket that was not previously known to be druggable.
The team says the approach highlights the importance of screening for drugs in diverse, creative ways.
If we had just screened looking for compounds with a particular function, we would not have identified all of these various functional molecules, and if we had just looked at the structure of CCNE1, we would not have found this binding pocket at all, says Zhang.
More research is needed to discover whether the new compounds have potential utility in treating cancer or other diseases in which CCNE1 plays a role. Next, the scientists plan to apply their paralog-hopping method to other pairs of proteins important for tumorigenesis.
In addition to Cravatt and Zhang, authors of the study, An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes, include Zhonglin Liu, Sang Joon Won, Divya Bezwada and Bruno Melillo of Scripps Research; and Marsha Hirschi, Oleg Brodsky, Eric Johnson, Asako Nagata, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen, Todd VanArsdale, Adam M. Gilbert, Matthew M. Hayward, Al E. Stewart and Andrew R. Nager of Pfizer, Inc.
This work was supported by funding from the National Cancer Institute (R35 CA231991) and Pfizer.
Chemistry Cravatt, Benjamin
North America Stories
29/01/2026
MELBOURNE, Fla., January 29, 2026 - L3Harris Technologies (NYSE: LHX) reports fu...
29/01/2026
Bluey' Wins Second Consecutive Top Streaming Title of the Year with 45 Billi...
29/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
29/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
29/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
29/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
29/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
29/01/2026
Boston Conservatory Orchestra Presents East Coast Premiere of Peter and Leonardo...
29/01/2026
Back to All News
Love is Blind: Sweden Returns for a Third Season - Premiering ...
29/01/2026
Back to All News
Unmask Bridgerton' Season 4 With Our Complete Coverage Guide
Yerin Ha as Sophie Baek and Luke Thompson as Benedict Bridgerton in Season ...
29/01/2026
Back to All News
Extraordinary Crime Mysteries, Mythical Worlds and High-Stakes...
29/01/2026
Editor's note: This post is part of Into the Omniverse, a series focused on ...
29/01/2026
Get ready to game - the native GeForce NOW app for Linux PCs is now available in beta, letting Linux desktops tap directly into GeForce RTX performance from the...
28/01/2026
Top L-R: The Liars, Jazz Infernal, Living with a Visionary
Second Row L-R: Paper Trail, The Baddest Speechwriter of All, Crisis Actor
Third Row: The Boys and ...
28/01/2026
Airlines, cruise and tour operators double down on ad spend as Australians' prioritise travel
Sydney January 28, 2026 - New Nielsen Ad Intel data shows a...
28/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
28/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
28/01/2026
Marshall Electronics launches the CV420-27X, its next-generation ultra-high-definition (UHD) IP camera, at ISE 2026 (Stand 4N900). Engineered for modern IP-base...
28/01/2026
Grass Valley has announced that Television Mobiles Ltd. (TVM), one of Europe's leading independent outside broadcast providers, has carried out a major refu...
28/01/2026
AI, graphics and virtual software power new production capabilities
FOR-A is bringing remarkable new technologies to FOMEX, the Future of Media Exhibition (ex...
28/01/2026
Continuing a longstanding collaboration, Riedel Communications and Nordic media technology company Media Tailor have once again joined forces to deliver a state...
28/01/2026
Pebble has appointed Paul Nagle-Smith as vice president for customer fulfilment, strengthening its senior leadership focus on customer delivery and operational ...
28/01/2026
Cloud playout solutions provider, Veset has announced that leading Mexican broadcaster, TV Azteca is using Veset Nimbus on AWS as a disaster recovery (DR) playo...
28/01/2026
Ensuring it can keep pace with a rapidly evolving live sports market, Balkan broadcast facility provider MVP Most Valuable Production has upgraded its flags...
28/01/2026
Akamai Technologies, Inc. (NASDAQ: AKAM), the cloud solutions provider that powers and protects life online, and Yospace, the leader in dynamic ad insertion tec...
28/01/2026
The renowned Reykjavik City Theatre (RCT) recently underwent a major intercom system upgrade using Clear-Com solutions. This milestone project utilizes Clear-C...
28/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
28/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
28/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Bluesky
Email...
28/01/2026
Boston Conservatory Orchestra Premieres a New Piano Concerto by Peter and Leonar...
28/01/2026
Back to All News
Netflix's Kohrra Season 2 Unveils A Thrilling Whodunnit Tr...
28/01/2026
Back to All News
What Next? Netflix Presents the Latest German-Speaking Series,...
28/01/2026
Quantum technologies are rapidly emerging as foundational capabilities for economic competitiveness, national security and scientific leadership in the 21st cen...
28/01/2026
Back to All News
The Wait Is Over: Teaser Trailer Drops for Jo Nesbo's Dete...
28/01/2026
Back to All News
Netflix Announces a Fictional Miniseries Inspired by the Marta del Castillo Case
Entertainment
28 January 2026
GlobalSpain
Link copied to ...
28/01/2026
Back to All News
Netflix Announces Santiago Mitres New Film Starring Ver nica L...
28/01/2026
Back to All News
Netflix Unveils the Teaser Trailer for Berlin and the Lady wit...
27/01/2026
L-R: Jonathan Cuchacovich, Sonia Kennebeck, Alan Fischer, Daeil Kim, Andrew Sta...
27/01/2026
Nielsen will continue to drive growth and provide local audience measurement
in...
27/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Pinterest
Bluesky
Email...
27/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Pinterest
Bluesky
Email...
27/01/2026
Share Share by:
Copy link
Facebook
X
Linkedin
Pinterest
Bluesky
Email...
27/01/2026
Amagi Media Labs Limited, the only cloud-native SaaS provider offering end-to-end solutions across live production, content preparation, distribution, and monet...
27/01/2026
Miri Technologies Inc. today unveiled its V410 live 4K video encoder/decoder for streaming, IP-based production workflows and AV-over-IP distribution. Designed ...
27/01/2026
The Paul E. Tsongas Center at UMass Lowell in Massachusetts has chosen Ikegami cameras for incorporation into its broadcast-quality television production facili...
27/01/2026
SipRadius, specialists in secure, low latency media transport, will show the pro AV community its end-to-end solution for high quality content distribution and ...
27/01/2026
Hiltron will highlight the fruits of its 45-plus years of experience in satellite communications system integration and product development at the annual GovSat...
27/01/2026
Klvr will demonstrate how its Charger Pro solution is delivering cost reduction and performance benefits for live entertainment and pro AV markets at ISE 2026 (...
27/01/2026
Amino, a global media technology leader in enterprise video and digital signage, today announced that its Integrated Systems Europe (ISE) 2026 booth (4N700) wil...
Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
